The EMBO Journal8d
Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Acquired resistance to PD-L1 inhibition can rewire the interferon-regulated secretory machinery in tumor cells, altering the ...
BioSpace8d
BioNTech Builds Case for PD-L1/VEGF Bispecific With Promising Breast Cancer Data
BNT327, now in early-phase trials, is part of a class of drugs that could one day challenge Keytruda’s dominance. BioNTech ...
Business Wire1mon
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
This study will focus on the treatment of newly diagnosed locally advanced primary head and neck cancer patients with no lymph node involvement and low (TPS <10) PD-L1 tumor expression.